Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Raw Materials (2018 - 2025)

Protalix BioTherapeutics has reported Raw Materials over the past 10 years, most recently at $6.0 million for Q4 2025.

  • Quarterly results put Raw Materials at $6.0 million for Q4 2025, up 31.46% from a year ago — trailing twelve months through Dec 2025 was $6.0 million (up 31.46% YoY), and the annual figure for FY2025 was $6.0 million, up 31.46%.
  • Raw Materials for Q4 2025 was $6.0 million at Protalix BioTherapeutics, up from $5.0 million in the prior quarter.
  • Over the last five years, Raw Materials for PLX hit a ceiling of $6.0 million in Q4 2025 and a floor of $3.0 million in Q2 2021.
  • Median Raw Materials over the past 5 years was $4.2 million (2023), compared with a mean of $4.0 million.
  • Biggest five-year swings in Raw Materials: dropped 21.94% in 2021 and later surged 40.51% in 2023.
  • Protalix BioTherapeutics' Raw Materials stood at $3.2 million in 2021, then grew by 10.8% to $3.5 million in 2022, then rose by 19.04% to $4.2 million in 2023, then rose by 8.93% to $4.5 million in 2024, then surged by 31.46% to $6.0 million in 2025.
  • The last three reported values for Raw Materials were $6.0 million (Q4 2025), $5.0 million (Q3 2025), and $4.4 million (Q2 2025) per Business Quant data.